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Background: Half of the familial aggregation of ovarian cancer can’t be explained by any known risk genes,
suggesting the existence of other genetic risk factors. Some of these unknown factors may not be traditional
protein encoding genes. MicroRNA (miRNA) plays a critical role in tumorigenesis, but it is still unknown if variants
in miRNA genes lead to predisposition to cancer. Considering the fact that miRNA regulates a number of tumor
suppressor genes (TSGs) and oncogenes, genetic variations in miRNA genes could affect the levels of expression of
TSGs or oncogenes and, thereby, cancer risk.
Methods and Results: To test this hypothesis in familial ovarian cancer, we screened for genetic variants in thirty
selected miRNA genes, which are predicted to regulate key ovarian cancer genes and are reported to be
misexpressed in ovarian tumor tissues, in eighty-three patients with familial ovarian cancer. All of the patients are
non-carriers of any known BRCA1/2 or mismatch repair (MMR) gene mutations. Seven novel genetic variants were
observed in four primary or precursor miRNA genes. Among them, three rare variants were found in the precursor
or primary precursor of the miR-191 gene. In functional assays, the one variant located in the precursor of miR-191
resulted in conformational changes in the predicted secondary structures, and consequently altered the expression
of mature miR-191. In further analysis, we found that this particular variant exists in five family members who had
ovarian cancer.
Conclusions: Our findings suggest that there are novel genetic variants in miRNA genes, and those certain genetic
variants in miRNA genes can affect the expression of mature miRNAs and, consequently, might alter the regulation
of TSGs or oncogenes. Additionally, the variant might be potentially associated with the development of familial
ovarian cancer.
Background
Epithelial carcinoma of the ovary is one of the most
common gynecologic malignancies in women [1].
Approximately 70% of ovarian cancer patients are diag-
nosed in an advanced stage. The 5-year survival rate of
women with ovarian cancer is approximately 40% and
has not significantly changed over the last two decades,
despite advances in treatment. It has been demonstrated
that prophylactic removal of ovaries in women at high
risk for developing ovarian cancer is an effective preven-
tion strategy and is especially applicable to women who
are genetically predisposed to ovarian cancer. Therefore,
identification of women who are predisposed to ovarian
cancer at an early age is clearly needed. Unfortunately,
so far, our understanding of the genetic predisposition
to ovarian cancer is limited. Family history is the stron-
gest known risk factor for ovarian cancer. Compared to
a 1.6% lifetime risk of developing ovarian cancer in the
general population, women with one first-degree relative
with ovarian cancer have a 5% risk and women with two
first-degree relatives have a 7% risk. The most common
form of familial ovarian cancer can be attributed to
mutations in either of the BRCA1/2 genes, which
account for 5-13% of ovarian cancer cases in Western
countries and for half of the familial aggregation of this
disease [2-5]. This suggests that other unidentified
genetic events may contribute to ovarian cancer.
miRNAs are short, noncoding RNAs that have been
identified in the genomes of a wide range of multicellular
life forms as well as viruses. miRNAs can regulate gene
expression by directly binding to the 3’UTR regions of
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(TSGs) or oncogenes, etc. It is known that there is a wide-
spread misexpression of miRNAs in many cancer tissues
[6,7], including ovarian cancer, but little is known regard-
ing how inherited variability in miRNA genes may predis-
pose towards cancer. In our previous analysis in 42
patients with familial breast cancer, we identified 7 novel
genetic variants in 7 miRNA genes [8]. Among these 7
variants, an A to G change in pre-miR-30c-1 and a C to A
change in pri-miR-17 were only observed in patients who
are non-carriers of known BRCA1/2 mutations. In further
functional analysis of these two variants, we found both of
them could cause conformational changes in the predicted
secondary structures and subsequently modify the expres-
sion of mature miRNAs. More interestingly, we observed
that miR-17 could bind to the 3’UTR of BRCA1 mRNAs
in the target in vitro assay, suggesting that the BRCA1
gene is a target gene for miR-17. In addition, several stu-
dies have demonstrated that rs2910164 in pre-miR-146a is
a risk modification factor for papillary thyroid carcinoma
and liver cancer as well as early age of familial breast and
ovarian cancer diagnosis [9-11]. Taken together, these
data suggest that variations in miRNA genes may affect
miRNA function, and potentially confer cancer suscept-
ibility through regulation of key TSGs and oncogenes.
To examine whether genetic variants in miRNA genes
might be able to explain some of the unidentified
genetic predisposition in familial ovarian cancer, we
screened genetic variants in select miRNA genes in
ovarian cancer patients who are non-carriers of any
known BRCA1/2 or MMR gene mutations. Our hypoth-
esis is that genetic variations in miRNA genes, if inher-
ited in the germline, could affect the levels of expression
of TSGs or oncogenes and, thereby, ovarian cancer risk.
Methods
Study population
This study included genomic DNA samples from lym-
phocytes of eighty-three non-related probands from
families with inherited ovarian cancer. The samples
were obtained from the Gilda Radner Familial Ovarian
Cancer Registry (GRFOCR). They were identified from
families with inherited ovarian cancer in which at least
two first or second degree relatives had epithelial ovar-
ian cancer diagnosed at any age. All of the samples were
from Caucasian women, who were non-carriers of
BRCA1/2 or MLH1/MSH2 mutations, with age at diag-
nosis ranging from 25 to 83 years. The study was
approved by the institutional IRB board.
miRNA selection
In this study, we focused on miRNA genes which are
predicted to regulate key ovarian cancer genes (such as,
BRCA1/2,/ 2, KRAS, PTEN, TGFb R2, CTTNB1, BRAF,
HNF-1b, MLH1 and MSH2) and are reported to be mis-
expressed in ovarian tumor tissues. Probability of Inter-
action by Target Accessibility (PITA) [12], a
computational algorithm that models miRNA and
mRNA binding, was used to identify the putative miR-
NAs which are predicted to regulate key ovarian cancer
genes. In addition, we have included several miRNAs
whose are reported by Viola [6] to be misexpressed in
several different types of tumor tissues, including ovar-
i a nt u m o r .I nt o t a l ,t h i r t ym i R N Ag e n e sw e r ei n c l u d e d
in this study. They were hsa-mir-132, 140, 143, 154,
185, 197, 205, 370, 9, 139, 200a, 320, 33, 381, 20a, let7,
106b, 188, 198, 216, 191, 221, 222, 26b, 29a, 29b, 29c,
93, 19a and 21.
Sequence Analysis
For each miRNA gene, we obtained its precursor
sequence from the microRNA registry http://microrna.
sanger.ac.uk/ and its corresponding genome region by
Blast analysis http://blast.ncbi.nlm.nih.gov/Blast.cgi. The
genomic region corresponding to each precursor
miRNA, including at least 100 bp at the 5’ and 3’ ends,
and covering the primary precursor of miRNA was
amplified. For the miRNAs located in clusters less than
1 kb apart, the entire corresponding genomic region was
amplified. The PCR cycling conditions for the assay
were 94°C for 5 minutes, followed by thirty-five cycles
at 94°C for 30 seconds, 60°C for 30 seconds and 72°C
for 30 seconds, with a final extension step at 72°C for 7
minutes. The amplified PCR products were sequenced
using the dideoxynucleotide chain termination method.
Both strands of the amplified PCR products were
sequenced with an ABI-PRISM 3730xl Autosequencer
(Aplied Biosystems, USA) in the Roswell Park Cancer
Institute (RPCI) Biopolymer Core. For quality control,
random duplicate samples (5%) were run for each
sequence analysis.
Prediction of miRNA secondary structure and calculation
of optimal free energy
Secondary structures and the minimum optimal free
energies for each pair of wild-type and variant primary
precursor of miRNA sequences, obtained from sequen-
cing, were predicted using the RNAhybrid program
http://bibiserv.techfak.uni-bielefeld.de/rnahybrid/submis-
sion.html. In all cases, the folded structures with mini-
m a lf r e ee n e r g yw e r ed e p i c t e d .T h ed e f a u l ts e t t i n gw a s
used for the program. The instructions for the program
were followed.
Computational algorithm to predict targets
Probability of Interaction by Target Accessibility (PITA)
was used to identify the putative miRNA targets [12].
PITA is a parameter-free thermodynamic model, which
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ity in target prediction. This program has been shown
to predict validated targets more accurately than any
other program. The default setting was used for the pro-
gram. The instructions for the program were followed.
miRNA cloning, expression, and detection
To study the effect that genetic variants have on the
expression levels of mature miR-191,w ei n s e r t e dt h e
DNA fragments containing primary precursors of
miRNA (Pri-miRNA) with either wildtype or variant
genotype into pcDNA3.3 mammalian expression vectors
(Invitrogen, Carlsbad, CA) by using the pcDNA™3.3-
TOPO® TA Cloning® Kit. Expression constructs were
transfected into SKOV-3 ovarian cancer cell lines using
DOTAP Liposomal Transfection reagents (Roche, India-
napolis, IN) according to the manufacturer’s recommen-
dations. After 48 hours, miRNAs were isolated using the
mirVana™ miRNA Isolation Kit (Applied Biosystems,
CA). The expression levels of mature microRNAs were
measured by Taqman based microRNA assays (Applied
Biosystems, CA) with the use of the ABI StepOne sys-
tem (Applied Biosystems, CA). The relative amount of
each miRNA to the amount of the tRNA for initiator
methionine was determined using the equation 2
-dCT,
where dCT =( C TmiRNA -C TU6). Each experiment was
triplicated and the mean of the triplicates was used. For
each experiment, a negative control (SKOV-3 cells
transfected with empty vector) was added. The signal
from the negative control was deducted from the
analysis.
Quantification of target gene expression
To confirm the target prediction, we applied Real-time
Taqman-based RT-PCR to quantify the expression of
selected predicted target genes for miR-191 in SKOV-3
cells transfected with pcDNA3.3 plasmids with or with-
out miR-191 gene using similar methods for transfection
and mRNA isolation as described above. The tested tar-
get genes were MLH1 and FANCD2. ABI Taqman gene
expression assays (Applied Biosystems) were used for
the mRNA quantification. b- a c t i nw a su s e da sa n
internal control gene to normalize the data. Each experi-
ment was triplicated and the mean of the triplicates was
used.
Statistical analysis
Student t test was used to compare mean expression
levels for significant differences between the wildtype
and variant alleles of miR-191 in miRNA expression
assay. A P-value < 0.05 was considered statistically sig-
nificant, and all statistical tests were two-sided. All ana-
lyses were performed using STATA software (Version
9.0, STATA Inc, College Station, TX).
Results
In total, we found seven novel genetic variants in four
miRNA genes (Table 1). Two variants were in the pre-
cursor of miRNA (miR-191 and miR-29B-2),5w e r ei n
the primary precursor of miRNA, and none were in
mature miRNA, signifying the high levels of conserva-
tion. The variant allele frequencies were rare for all of
the variants. Interestingly, we observed three novel var-
iants in miR-191 gene, one in the precursor region and
two in the primary region (Figure 1). miR-191 has been
observed to be misexpressed in a variety of human
tumors, including breast, ovarian, prostate, colorectal,
etc. However, the functional significance of miR-191 in
familial ovarian cancer is unknown. Using the PITA pre-
diction algorithm, we found several cancer related genes
are the potential targets for miR-191. They include
IGF1R, FANCC, FANCF, FANCD2, and MLH1, etc.
Given the presence of novel genetic variants affecting
the precursor of miRNA, but not the mature miRNA
itself, we tested whether such variants could affect their
secondary structure and thereby block processing into
the functional mature miRNA. For miR-191 gene, the
secondary structures for wildtype and the three variants
were predicted. Both variants in the primary precursor
region of the miR-191 gene didn’tc h a n g et h es e c o n d a r y
structures of miR-191. On the contrary, the C to A
genetic variant in the precursor of miR-191 (pre-mi191)
slightly altered the secondary structure of miR-191
( F i g u r e2 ) .T h eAa l l e l ed e s t r o y e dab a s e - p a i r i n g ,w h i c h
Table 1 Novel Genetic variants in selected miRNA genes in ovarian cancer patients
miRNA genes Nt Change Location Allele frequency Selected target genes (examples)*
miR -17 C/T Pri-miRNA 0.012 BRCA1, PTEN, p53 and ATM
hsa-mir-191 C/T Pri-miRNA 0.006 IGF1R, FANCC, FANCF, FANCD2, MLH3
C/G pri-miRNA 0.012
C/A Pre-miRNA 0.006
hsa-mir-29b-2 C/T pri-miRNA 0.042 DNMT3A, IGFI, CCND2, BCL2
A/T pre-miRNA 0.021 DNMT3A, IGFI, CCND2, BCL2
hsa-mir-188 T/C pri-miRNA 0.006 CCND2, XRCC2, IGFI, E2F
* This non-inclusive list shows only the potential targets known to be involved in tumorigenesis. Other, unrelated, targets may exist for these miRNAs.
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ondary structure of this pre-miRNA. The optimal free
energy was decreased from -49.91 Kcal/Mol for C allele
to -42.1 kcal/Mol for A allele, suggesting a less stable
secondary structure for A allele than C allele.
Processing of miRNA precursors by the RNase Drosha
requires the secondary hairpin structure characteristic of
these RNA molecules and specific sequence elements
within the primary precursor of miRNA. To assess the
effect of the predicted changes in secondary structure
on mature miRNA expression, we cloned the primary
precursor of miR-191 containing C or A allele into
pcDNA3.3, transfected the constructs into SKOV-3
ovarian cancer cell lines, and measured expression levels
of mature miR-191 by Taqman based microRNA assays.
We found that the expression levels of mature C allele
miR-191 were significantly higher than those of the A
allele (P = 0.021) (Figure 3). The expression levels of
mature miR-191 were over 2 times higher in C allele
than A allele, suggesting that this polymorphism in the
precursor of miR-191 could enhance the mature miRNA
production. A similar approach was used to test whether
the two other genetic variant in the primary precursor
of miR-191 could affect the mature miRNA expression.
As expected, we didn’t observe any significant changes
in mature miR-191 expression between wildtype and the
primary-precursor variant of miR-191 (Figure 3).
To further confirm the target prediction, we applied
Taqman-based real-time RT-PCR to detect whether the
expression of MLH1 and FANCD2 were affected when
SKOV-3 cells were transfected with miR-191 expression
vector. Compared to SKOV-3 cells transfected with the
empty vector, SKOV-3 cells transfected with miR-191
expression vector had significantly lower MLH1 and
FANCD2 expression (50% for MLH1, P = 0.024; 67% for
FANCD2, P = 0.032), suggesting that MLH1 and
FANCD2 were target genes for miR-191 (Figure 4).
For the genetic variant in the precursor of the miR-191
gene, we further investigated the genetic inheritance of
the variant in the extended family members. For the C to
A change in miR-191, DNA samples for 13 relatives were
available. In these 13 relatives, 5 had CA genotypes and
the 8 had CC genotypes. Including the proband, three
individuals who had the CA genotype were diagnosed
with ovarian cancer. The relatives who had the CC geno-
type all appeared healthy when they were recruited. The
detailed pedigree is shown in Figure 5.
Discussion and Conclusions
Because of the particular way in which miRNA func-
tions, by targeting a number of functionally important
protein-encoding genes, it is appealing to propose that
genetic variations in miRNA genes and/or their respon-
sive elements in the target mRNAs might represent a
newly described mechanism of cancer predisposition
[13]. In this study, we found several novel genetic var-
iants in the primary precursors or precursors of miRNA
genes in patients with familial ovarian cancer, but who
are non-carriers of any known BRCA1/2 or MLH1/
Figure 1 The locations of the genetic variants in the primary precursor of miR-191 in relation to mature miRNA (in red) and precursor
miRNA (in blue). The variants are highlighted in yellow.
Figure 2 Sequence variation in the precursor of miR-191 can
translate intro structural alterations. The RNA secondary structure
was predicted by RNAHYbrid for WT pri-miR-191 and its novel
variant. Only the most stable secondary structures with the lowest
free energy are depicted.
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Page 4 of 8Figure 3 Real-time quantitative PCR for mature miR-191 expression in the cells transfected with pcDNA3.3 vector containing miR-191
wildtype or one of three variants. Data are means (± SD) from three independent experiments. Data are normalized with reference tRNA, as
mentioned in the text. P value was calculated from a two-sided, one-sample t test.
Figure 4 Real time quantitative PCR for MLH1 and FANCD2 gene expression in the cells transfected with pcDNA3.3 vector containing
miR-191 or the empty vector. Data are means (± SD) from three independent experiments. Data are normalized with reference b-actin, as
mentioned in the text. P value was calculated from a two-sided, one-sample t test.
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genetic susceptibility to ovarian cancer. One rare variant
in the precursor of miR-191 results in conformational
changes in the predicted secondary structures, and con-
sequently alter the expression of mature miRNA. In
further family analysis, we found that this variant exists
in four extended family members, including two indivi-
duals who were diagnosed with ovarian cancer. At the
same time, family members who are not carriers of this
rare variant all appeared to be cancer free when they
were recruited.
Consistent with our previous study in breast cancer
and other literature reports, our screening did not reveal
any genetic variants in mature miRNAs, demonstrating
the evolutionary conservation of miRNA genes. In order
to further explore whether these rare variants exist in
the general population, we genotyped 100 healthy
women. As we expected, we didn’t observe any of these
rare variants in these healthy women. Although a “com-
mon disease-common allele” model has been accepted
for most of the sporadic cancers, the situation in familial
cancers might be different. So far, most of the genetic
risk alleles contributing to familial ovarian cancer are
rare mutations in BRCA1/2 or MLH1/MSH1 genes. No
common alleles have been found to be associated with
familial ovarian cancer. Therefore, just like familial
breast cancer, the model that best reflects familial ovar-
ian cancer might be a “common disease-multiple rare
alleles” model. The findings from this study provide the
evidence to support this model.
The contribution of rare variants with medium or low
penetrance in cancer predisposition is largely unknown.
On one hand, because of their rarity, their population
attributive risk tends to be low. On the other hand, it
has been found that rare variants are more likely to
have functional significance compared to common var-
iants. In a recent publication by the Amos group, they
reported that the minor allele frequency (MAF) distribu-
tion of functional variants was shifted towards rare var-
iants compared with the variant distribution of neutral
variants [14]. They observed an inverse relationship
between MAF and the proportion of functional variants,
suggesting that rare variants tend to have more biologi-
cal function compared to common variants. In this
study, we found a rare variant in the precursor of the
miR-191 gene that alters the secondary structure of the
precursor miR-191, and thereby affect the expression of
mature miR-191.
It has been hypothesized that the disturbance of the
secondary structure of the miRNA precursor by
sequence variations may affect the maturation process
of miRNA. Consistent with this hypothesis, in this
study, we found that the C to A variation causes a sig-
nificant structure change in the stem region of the miR-
191 precursor and results in the reduced production of
mature miR-191. Similar findings have also been
observed in our previous study in familial breast cancer
and several other studies [8,15,16]. We found an A to G
change in pre-miR-30c-1 and a C to A change in pri-
miR-17 in familial breast cancer patients who are non-
carriers of known BRCA1/2 mutations [8]. In further
functional analysis of these two variants, we found both
of them could cause conformational changes in the pre-
dicted secondary structures and, subsequently, modify
the expression of mature miRNAs. The expression of
mature miR-125a is decreased when a G:C match is
replaced by a U:C mismatch in the stem region [15].
Furthermore, introduction of an artificial mutation to
Figure 5 Family pedigree structure for the proband who carries the novel variant in the precursor of miR-191. To simplify the structure,
we only show those relatives for whom we have DNA samples. Circle: women, Square: men, and dark circle: ovarian cancer patients.
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large bulges in the stem regions were detrimental to the
production of miRNA [16].
Whether miR-191 plays any role in familial ovarian
cancer is unknown. miR-191 is a member of the core
miRNAs which are frequently misexpressed in a variety
of human tumors, including, breast, ovarian, prostate,
and colorectal [6]. So far, there is no report on why miR-
191 is misexpressed and which target genes miR-191
might regulate. Using PITA algorithms, we found that
miR-191 could potentially regulate several important
genes which are related to familial ovarian cancer. They
include MLH1, FANCC, FANCF and FANCD2.I no u r
analysis, we found that SKOV-3 cells transfected with
miR-191 expression vector had significantly lower MLH1
a n dF A N C D 2e x p r e s s i o n( 5 0 %f o rM L H 1a n d6 7 %f o r
FANCD2), compared to SKOV-3 cells transfected with
empty vector. Our results provide an indirect evidence to
support the target prediction. The contribution of mis-
match repair (MMR) genes to familial ovarian cancer has
been well-documented. A group of rare mutations in
MLH1 gene contribute to familial ovarian cancer [17].
The relationship between the Fanconi anemia (FA) genes
(FANCC, FANCF and FANCD2) and familial ovarian can-
cer is intriguing. It has been reported that tissue-
restricted hypersensitivity to cross-linking agents is a fre-
quent finding in ovarian cancer patients or high risk
women with no BRCA1/2 mutations [18]. Ectopic expres-
sion of normal FANCD2 cDNA increased FANCD2 pro-
tein and induced MMC resistance in both hypersensitive
cell lines tested, illustrating the key role of FANCD2 in
the sensitivity of cross-linking agents. However, no
FANCD2 coding region or promoter mutations were
found, and there was no genomic loss or promoter
methylation in FANCD2 in ovarian tumor tissues. This
suggests that there might be other regulation mechan-
isms (such as miRNAs) which regulate FANCD2’s
expression in ovarian tissues.
One way to assess the genetic susceptibility of rare
variants is to look at the inheritance of the variants in
the families. In this study, we found that 5 out of a total
of 13 relatives had CA genotypes and the other 8 had
CC genotypes. Including the proband, three individuals
who had the CA genotype were diagnosed with ovarian
cancer. The relatives who had the CC genotype all
appeared healthy when they were recruited. It appears
that, to a certain degree, this rare variant in the precur-
sor of miR-191 co-segregates with familial ovarian can-
cer, although we don’t have enough families or extended
family members to perform a meaningful pedigree ana-
lysis. Therefore, further screening of this rare variant in
other families is necessary.
The global expression of miRNA in ovarian tumor tis-
sues has been studied [6,7]. For example, Zhang et al.
used an array comparative genomic hybridization
(aCGH) approach to identify miRNA loci gained/lost in
ovarian cancer [7]. Of 283 miRNA loci analyzed, 105
(37.1%) were determined to be significantly altered in
their copy number in 93 primary ovarian tumor tissues.
Quantitative RT-PCR demonstrated that the expression
of miRNAs was consistent with the DNA copy number
status for 73.1% of miRNAs, demonstrating that DNA
copy number alterations may have an important effect
on miRNA expression. Of interest is the loss of the
miR-17-92 locus in not only ovarian tumor but also
breast tumors and melanoma. In our study, we found a
rare genetic variant in miR-17 gene. Although our study
focuses on inherited genetic variants and miRNA
expression studies focus on somatic alterations of
miRNA expression, it would be interesting to look at
the relationship between germline variants in miRNA
genes and miRNA expression in ovarian tumor tissues.
There are several limitations in this study. For exam-
ple, it might be interesting to look at the links between
genetic variants in miR-191 and target gene expression
in matched tumor tissues. Unfortunately, the tumor tis-
sues are not available for these patients. It would be
nice to assess the relationship between these genetic
variants in miRNA genes and the patients’ phenotypes,
such as clinical and demographic characteristics. Unfor-
tunately, we don’t have detailed information for this
study population.
This is the first report to show the existence of genetic
variants in selected miRNA genes in patients with famil-
ial ovarian cancer. We found that a genetic variant in
the precursor of miR-191 could significantly change the
secondary structures and, consequently, alter the expres-
sion of mature miRNAs. Future large population or
family studies are needed to assess the contribution of
miRNA variants to cancer risk as well as cancer pheno-
types. Advanced in vivo molecular assays are warranted
to further confirm our findings in functional analyses.
Nevertheless, our data suggest that functional variants
in miRNA genes might alter the expression of mature
miRNAs. It opens the possibility that miRNA genes
might be novel ovarian cancer predisposition genes,
although this still needs to be cautiously tested.
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